Stocks股票 / Health Care / HALO
HALO US listed · USD美股 · 美元
Halozyme Therapeutics, Inc. is an American biotechnology company.Halozyme Therapeutics, Inc. 是一家美国生物技术公司。
The latest call, in context把最新财报放回历史脉络
A synthesized event record across management commentary and recorded metrics. Read as context; verify exact wording in the transcript before relying.综合管理层表述与记录指标形成事件档案。仅供参考;使用前请在电话会原文中核对准确措辞。
Live company record实时公司记录
JavaScript loads the source-bounded event record here. Open Terminal if the live module does not start.JavaScript 会在此加载受来源约束的事件记录。如实时模块未启动,请打开终端。
Continue with full transcript history继续查看完整电话会历史 ↗Price chart价格图表
Technicals技术面
daily bars日线数据 · 2026-09-28Earnings财务业绩
next report下次财报 2026-11-02Estimates roughly stable预期基本稳定
Beat in 3 of last 4 quarters近 4 季中 3 季超预期
EPS surprise vs consensus, last quarters每股收益相对预期的超预期幅度(近几个季度) · average平均 -21.1%
Valuation估值
Expensive vs sector相对行业偏贵| Multiple指标 | HALO | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(历史) | 42.33x | 29.58 | |
| P/B市净率 | 274.83x | 3.30 | |
| P/S市销率 | 9.61x | 3.19 | |
| Earnings yield盈利收益率 | 2.36% | 2.56 | |
| FCF yield自由现金流收益率 | 4.80% | 4.11 | |
| Shareholder yield股东收益率 | 2.55% | 1.87 | |
| EV/EBITDA企业价值/EBITDA | 32.11x | 18.26 | |
| P/FCF市值/自由现金流 | 20.81x | 21.34 |
Financials财务数据
fiscal years财年Leverage杠杆
Capital allocation资本配置
Debt coming due到期债务
FY2025 10-KIn the 12-month bucket following fiscal period end 2025-12-31, it reported $11.8M due — about 1% of its disclosed principal.在财年期末 2025-12-31 之后12个月的区间内,已披露到期本金为 $11.8M,约占其披露本金的 1%。
All maturity buckets are measured from fiscal period end 2025-12-31, not from today.所有到期区间均从财年期末 2025-12-31 起算,而非从今天起算。
Cash reported at 2025-12-31: $133820000.截至 2025-12-31 披露的现金:$133820000。 Operating cash flow exceeded or equaled equipment spending over 2025-01-01 to 2025-12-31; no cash burn to measure.在 2025-01-01 至 2025-12-31 期间,经营现金流不低于设备支出,无可衡量的现金消耗。
Cash reported at 2025-12-31 covers 1130% of issuer-reported principal in the 12-month bucket following that fiscal period end.截至 2025-12-31 披露的现金可覆盖该财年期末之后12个月区间内发行人已披露到期本金的 1130%。
Cash shortfall against that reported principal: $0相对该已披露本金的现金缺口:$0。
Sources and cash-flow calculation来源与现金流计算
Figures are XBRL facts from one filing — no two years are mixed. Filing数据取自同一份文件中的 XBRL 事实,不跨文件拼接。文件
0001159036-26-000024, period ending报告期截至 2025-12-31, unit单位 USD.
Cache acquired缓存获取时间: 2026-09-26T08:01:50.169194+00:00.
6/6 buckets reported.个区间有披露。
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonthsLongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwoLongTermDebtMaturitiesRepaymentsOfPrincipalInYearThreeLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFourLongTermDebtMaturitiesRepaymentsOfPrincipalInYearFiveLongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
Annual period年度区间 2025-01-01 — 2025-12-31 · USD · 10-K · 0001159036-26-000024 · Filed提交日期 2026-02-17.
Cache acquired缓存获取时间: 2026-09-26T08:01:50.169194+00:00 · Evaluated as of评估截至 2026-09-29.
- Reported operating cash flow已披露经营活动现金流: $651558000
- Reported equipment spending (capex outflow)已披露设备支出(资本开支流出): $6970000
- Derived free cash flow (operating cash flow minus capex)计算所得自由现金流(经营现金流减资本开支): $644588000
Cash is the reported balance at period end. The runway scenario holds this annual cash-flow pace constant and excludes debt payments, restricted-cash adjustments and future financing.现金为期末已披露余额。现金跑道情景假设本年度现金流速度保持不变,不包括债务偿还、受限现金调整与未来融资。
Why is it moving为何波动
6 checks · nightly六项检查 · 每晚Ownership & smart money持仓与聪明钱
13FInsider activity:内部人动向: -$20.2M net (0 buyers, 4 sellers)-$20.2M 净值(0 买家,4 卖家)
Signal history信号历史
engine events引擎事件Company profile公司档案
Halozyme Therapeutics, Inc. is an American biotechnology company.Halozyme Therapeutics, Inc. 是一家美国生物技术公司。
- Margin compression despite revenue growth
- Receivables stretch
The whole US universe — S&P 1500 and Russell 2000 — read nightly.覆盖标普1500与罗素2000全部成分股 — 每晚更新解读。
Signals, options positioning, smart-money moves and factor DNA — the same engine that wrote this page covers 2,700+ US stocks.信号、期权持仓、聪明钱动向与因子基因 — 撰写本页的引擎覆盖2700多只美股。
Valuation vs sector估值对比行业
| Multiple指标 | This stock本股 | Sector median行业中位 | Cheaper than相对便宜 |
|---|---|---|---|
| P/E (trailing)市盈率(静态) | 42.3× | 29.6× | 27% |
| Price / Book市净率 | 274.8× | 3.3× | 0% |
| Price / Sales市销率 | 9.6× | 3.2× | 12% |
| EV / EBITDAEV/EBITDA | 32.1× | 18.3× | 21% |
| Earnings yield盈利收益率 | 2.4% | 2.6% | 46% |
| Free-cash-flow yield自由现金流收益率 | 4.9% | 5.5% | 43% |
| Shareholder yield股东综合回报率 | 2.5% | 1.9% | 59% |
Relative strength相对强度
Price history价格历史
| Period周期 | This stock本股 | S&P 500标普500 |
|---|---|---|
| 1 Week近1周 | +1.3% | +1.3% |
| 1 Month近1月 | +6.4% | +0.9% |
| 3 Months近3月 | +51.9% | +6.1% |
| 6 Months近6月 | +84.8% | +22.3% |
| Year to date年初至今 | +62.0% | +13.8% |
| 1 Year近1年 | +54.0% | +18.5% |
| 3 Years近3年 | +196.1% | +87.8% |
Trading information交易信息
Multi-year record多年财务记录
| 20202020 | 20212021 | 20222022 | 20232023 | 20242024 | 20252025 | |
|---|---|---|---|---|---|---|
| Revenue营业收入 | $268M | $443M | $660M | $829M | $1.0B | $1.4B |
| EPS每股收益 | $0.91 | $2.74 | $1.44 | $2.10 | $3.43 | $2.56 |
| Free cash flow自由现金流 | $53M | $298M | $235M | $373M | $468M | $645M |
| Gross margin毛利率 | 83.8% | 81.6% | 78.9% | 76.8% | 84.3% | 83.6% |
| Net margin净利率 | 48.2% | 90.8% | 30.6% | 34.0% | 43.7% | 22.7% |
| FCF margin自由现金流利润率 | 19.8% | 67.2% | 35.6% | 45.0% | 46.1% | 46.2% |
Latest fiscal year最近财年
Returns & growth回报与增长
Accounting quality checks会计质量检查
- Earnings quality: earnings cash-backed盈利质量:盈利有现金支撑
- Working capital: inventory & receivables lean vs sales营运资本:存货与应收相对销售保持精简
- Pricing power: gross margin −0.2pts over 6 years定价能力:毛利率 6 年下降 0.2 个百分点
- Capital discipline: assets +22.4% (aggressive expansion)资本纪律:资产 +22.4%(扩张激进)
- Balance sheet: Altman Z 4.75 — safe zone资产负债表:Altman Z 4.75——安全区
Indicator readings指标读数
Timeframe alignment多周期共振
Volatility regime波动状态
Surprise history超预期历史
| Quarter季度 | Reported实际 | Expected预期 | Surprise超预期 |
|---|---|---|---|
| Jun 2026 | $2.17 | $1.73 | +25.4% |
| Mar 2026 | $1.48 | $1.46 | +1.4% |
| Dec 2025 | $-0.35 | $2.07 | -116.9% |
| Sep 2025 | $1.63 | $1.54 | +5.8% |
Estimate revisions预期修正
Insiders & shorts内部人与空头
Recent fund flows近期基金流向
Month by month逐月统计
| Month月份 | Closed higher收涨占比 | Median move中位涨跌 | Years年数 |
|---|---|---|---|
| Jan1月 | 67% | +6.8% | 3 |
| Feb2月 | 67% | +4.4% | 3 |
| Mar3月 | 67% | +2.3% | 3 |
| Apr4月 | 0% | -3.1% | 3 |
| May5月 | 67% | +4.9% | 3 |
| Jun6月 | 67% | +16.7% | 3 |
| Jul7月 | 100% | +5.7% | 3 |
| Aug8月 | 75% | +20.1% | 4 |
| Sep9月 | 50% | +0.4% | 4 |
| Oct10月 | 0% | -11.4% | 3 |
| Nov11月 | 67% | +9.4% | 3 |
| Dec12月 | 0% | -3.6% | 3 |